A Multicenter, Prospective, Comparative, Randomized Clinical Trial to Compare and Evaluate the Efficacy and Safety of the Pulmonary Rehabilitation Software 'EB-S100' in Patients with Chronic obstructive pulmonary Disease, Against a Standard Treatment Control Group.

Emocog Co., Ltd.0 个研究点目标入组 64 人开始时间: 2025年11月7日最近更新: 2026年7月20日

适应症

试验速览

暂无简介。

•All of the following inclusion criteria must be met to participate in this clinical study.
•Adults aged 19 years or older
•Patients diagnosed with chronic obstructive pulmonary disease (COPD) according to the Korean clinical practice guidelines for COPD
•FEV1/FVC ratio < 0.7 on pulmonary function testing
•Patients diagnosed with COPD who require pulmonary rehabilitation exercise therapy
•Able to read and write Korean without difficulty
•Able to use mobile applications on general-purpose devices such as smartphones or tablet PCs without difficulty
•Subjects who voluntarily agree to participate in this clinical study

•Subjects meeting any of the following exclusion criteria will not be eligible to participate in this clinical study.
•Respiratory muscle dysfunction
•Psychiatric disorders that prevent communication or compliance with instructions
•Diseases or conditions that impair walking or make improvement in walking ability difficult, including cerebrovascular diseases, musculoskeletal disorders, or other severe malnutrition
•Other diseases that may result in death or disability within one year, including severe cancer, coronary artery disease, heart failure, or diabetes mellitus with severe complications
•Pregnant women
•Subjects deemed unsuitable for study participation at the investigator’s discretion

发起方

Emocog Co., Ltd.